Medical institutions ordered to cooperate in recall of hypertension drug
Medical institutions must cooperate with the authorities in the recall of hypertension drugs containing a carcinogenic impurity, the National Health Commission said on Monday.
On Sunday, China's top drug regulator urged provincial drug authorities to supervise a recall by pharmaceutical companies of all valsartan produced with raw materials supplied by Zhejiang Huahai Pharmaceutical Co, which is based in Linhai, Zhejiang province.
Huahai reported to the State Drug Administration on July 6 that it had found traces of NDMA, a substance that may cause cancer, in valsartan it produced. The company has recalled all its affected products from the Chinese market.
The National Health Commission said on Monday that no medical institutions could use valsartan drugs covered by the recall, but they can use valsartan made by other companies or other hypertension drugs, based on advice from doctors.
- Shanghai's Huaxin town showcases rural revitalization efforts
- Taiwan residents flock to mainland during holiday season
- National Day holiday box office exceeds 1.6b yuan
- China rushes farm machinery to key grain belt as rain threatens harvest
- Xinjiang scenic area suspends hiking after heavy snowstorm
- Typhoon Matmo weakens after hitting South China's Guangxi, relief efforts underway
